Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...
Is the promise of more affordable weight loss drugs too good to be true? Compounded semaglutide, explained.
"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...
What Analysts Think of Eli Lilly Stock Ahead of Earnings
Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Nature2d
The weight-loss drugs being tested in 2025: will they beat Ozempic?
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...